书目名称 | Chemotherapy Protocols and Infusion Sequence | 副标题 | Schedule Considerati | 编辑 | Iago Dillion Lima Cavalcanti | 视频video | http://file.papertrans.cn/225/224965/224965.mp4 | 概述 | Discusses infusion sequence to improve therapeutic outcomes in cancer treatment.Collates information about efficacy and/or toxicity of drug interactions in therapeutic combination.Facilitates the sear | 图书封面 |  | 描述 | This book aims to address the infusion sequence of the main protocols used in the treatment of varied solid cancers. Since an inadequate infusion sequence can compromise the patient‘s treatment, this work will provide support to professionals working in the field of oncology in assessing each chemotherapy infusion sequence. The introductory chapters present the definition, indication, and the risks and benefits of polypharmacy in cancer therapy, and discuss the importance of drug combination in cancer treatment. Chapter 2 focuses on the challenges and also the toxicity of combination therapy in cancer, while chapter 3 highlights the parameters that must be evaluated before defining the infusion sequence, such as pharmacodynamic and pharmacokinetic profiles, drugs’ stability when diluted or reconstituted, toxicological profile of each drug, among others.. The remaining chapters are divided by type of cancer. The content is focused on solid tumors, dividing the chapters according to breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, and neurological cancers. In each chapter the epidemiological profiles, pathophysiology, therapeutic modalities, and the main | 出版日期 | Book 2022 | 关键词 | Chemotherapy protocols; Polypharmacy; Genitourinary cancer protocols; Head and neck cancer protocols; Lu | 版次 | 1 | doi | https://doi.org/10.1007/978-3-031-10839-6 | isbn_softcover | 978-3-031-10841-9 | isbn_ebook | 978-3-031-10839-6 | copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |
1 |
Front Matter |
|
|
Abstract
|
2 |
,Polypharmacy in Cancer Therapy, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this first chapter, we discuss polypharmacy, its concept, and its use in chronic diseases. I emphasize the importance of polypharmacy in the treatment of patients with multimorbidities and its use in the treatment of cancer patients. I also discuss drug interactions that can occur in patients using polypharmacy, highlighting studies that bring data on drug interactions in cancer treatment, such as pharmacodynamic and pharmacokinetic interactions. I discuss the advantages of the association of drugs for the treatment of cancer, with an increase in the effectiveness of the treatment, reduction of toxicity, and improvement in the quality of life of patients. Finally, I talk about the risks of polypharmacy, such as the increase in the development of adverse reactions due to drug interactions and can potentiate the toxic effects of drugs.
|
3 |
,Combined Therapy for the Treatment of Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this second chapter, I approach cancer treatment, highlighting cytotoxic chemotherapy and biological therapy, classifying the therapies, and indicating the main drugs included in each anticancer therapy. In addition, I talk about combined therapy, which is based on the association of drugs with different mechanisms of action, promoting greater efficacy in cancer therapy, and I also highlight the main challenges of combined therapy, which should be taken into account when choosing the best combination for the treatment of a particular cancer. Finally, I discuss the toxicity profiles of the treatment of various cancers, such as toxicity related to the treatment of breast, lung, colorectal, prostate, cervix, and head and neck cancers.
|
4 |
,Importance of the Infusion Order in the Treatment of Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this chapter I discuss infusion therapy, what it is based on, when it is used, and what are its advantages and disadvantages in cancer treatment. I bring the classification of infusion types according to time, such as bolus infusion, rapid infusion and continuous infusion, and its purpose in the application of antineoplastic drugs. I discuss the differences between reconstitution and dilution of drugs, as well as their stability after reconstitution, highlighting the importance of choosing the diluent in the incompatibility of drugs that will be administered in sequence. I also discuss the risks of infusion, which are mainly related to the dermatological toxicity of antineoplastic agents, where extravasation can cause damage in cases ranging from ulceration to necrosis, and it is important to identify the classification of chemotherapy in relation to dermatological toxicity in vesicants and irritants. Finally, I bring the concept and the importance of planning the order of infusion of drugs, as an inadequate sequence can directly impact the treatment response, reducing the effectiveness and increasing the toxicity of antineoplastic therapy.
|
5 |
,Chemotherapeutic Protocols for the Treatment of Breast Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this chapter, I discuss breast cancer, bringing epidemiological data and talking a little about its pathophysiology, classification according to the molecular subtype, and the main therapeutic modalities of breast cancer. I discuss several chemotherapy protocols used in the treatment of adjuvant breast cancer, such as the AC, ACT, CMF, FEC, DAC, TDC, and DCARBT protocols, among others. I also discuss the protocols indicated for the treatment of locally advanced breast cancer and advanced breast cancer with the inclusion of drugs such as gemcitabine and vinorelbine, in addition to the monoclonal antibodies trastuzumab and pertuzumab. The infusion sequence suggestions are based on clinical studies and protocols available on hospital websites and in the 2017 chemotherapy protocol book. I emphasize the importance of evaluating the infusion sequence of chemotherapy protocols, due to the low number of studies that have as objective to evaluate the influence of the order of infusion on the efficacy and safety of the chemotherapy protocol in the treatment of breast cancer.
|
6 |
,Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this chapter, I discuss the main cancers of the gastrointestinal tract, including cancers of the colon and rectum, stomach, esophagus, pancreas, biliary tract, gallbladder, liver, among others, addressing their epidemiological profiles, in addition to bringing some data about pathophysiology of each cancer. I also discuss the protocols used according to cancer of the gastrointestinal tract, bringing efficacy data for each protocol and their infusion sequences. Some protocols mentioned in this chapter include FOLFOX, FOLFIRI, FOLFIRINOX, CAPOX, CAPOXB, CAPIRI, CAPIRIB, among others. Infusion sequence suggestions are based on clinical studies and protocols available on hospital websites and in the 2017 chemotherapy protocol book. As with the protocols used in the treatment of breast cancer (Chap. .), there are few studies that assess the influence of the infusion sequence on the efficacy and/or increase in the toxicity of the chemotherapy protocol.
|
7 |
,Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this chapter I discuss cancers that affect the genitourinary tract, talking a little about the pathophysiology of cancers of the bladder, prostate, testicle, and kidney. I also bring epidemiological data for each cancer and cite the main protocols indicated for each cancer, bringing protocol efficacy data, as well as the infusion schedule for each combination. Among the protocols mentioned, I approach BCGIFN, GEMDOC, MVAC, BEP, VIP, TIP, VEIP, and PEMAX, among others. Administration schedules were based on clinical studies and protocols available on hospital websites and in the 2017 chemotherapy protocol book. I emphasize once again, as in Chapters . and ., the importance of evaluating the influence of the drug administration schedule to assess whether the protocol’s efficacy and toxicity are schedule-dependent.
|
8 |
,Chemotherapeutic Protocols for the Treatment of Gynecological Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
This chapter brings the main gynecological cancers such as cancers of the ovary, cervix, endometrium, and gestational trophoblastic neoplasia. I discuss the epidemiological profile of each cancer and bring some data on the pathophysiology, staging, and treatment modalities. The main chemotherapy protocols are also addressed, such as CABR, CAPBEV, CISP, CAD, EMA-CO, DM, among others. Administration schedules were based on clinical studies and protocols available on hospital websites and in the 2017 chemotherapy protocol book. The low number of clinical studies evaluating the efficacy and toxicity of the protocols according to the infusion schedule limits the data and reinforces the need for studies aimed at evaluating the infusion sequence of chemotherapy protocols.
|
9 |
,Chemotherapeutic Protocols for the Treatment of Head and Neck Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
This chapter deals with head and neck cancers, highlighting nasopharyngeal, squamous cell carcinomas, and salivary tumors. I bring epidemiological, pathophysiological data, staging, and the main therapeutic modalities. I also discuss some protocols indicated for the treatment of head and neck cancers, such as the FUP, EP, PG, PC, PCP, PFP, VNC protocols, and among others. Administration schedules were based on clinical studies and protocols available on hospital websites and in the 2017 chemotherapy protocol book. The low number of clinical studies evaluating the efficacy and toxicity of the protocols according to the infusion schedule limits the data and reinforces the need for studies aimed at evaluating the infusion sequence of chemotherapy protocols.
|
10 |
,Chemotherapeutic Protocols for the Treatment of Lung Cancer, |
|
|
Abstract
|
11 |
,Chemotherapeutic Protocols for the Treatment of Neurological Cancer, |
Iago Dillion Lima Cavalcanti |
|
Abstract
In this chapter, I discuss neurological tumors, bringing epidemiological data and talking about the main types of neurological cancers such as gliomas, neuroectodermal, and pituitary tumors. The treatment modalities for these types of tumors are mentioned, as well as some therapeutic protocols indicated for neurological tumors, and their administration schedule. Among the mentioned protocols include CARV, TMZETO, PCV, and among others. The administration schedules cited in this chapter were based on data provided in scientific articles and protocols available on hospital websites and in the 2017 chemotherapy protocol book.
|
12 |
Back Matter |
|
|
Abstract
|
|
|